Second-line immunosuppressant administration for steroid-refractory immune-related adverse events in patients with lung cancer

Background Evidence for use of second-line immunosuppressants for immune-related adverse events (irAEs) is inadequate. Therefore, a multicenter analysis should assess the efficacy of second-line immunosuppressants for severe irAEs associated with different malignant diseases. Methods This descriptiv...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Cancer Immunology, Immunotherapy Immunotherapy, 2023-11, Vol.72 (11), p.3765-3772
Hauptverfasser:	Ogusu, Shinsuke, Harutani, Yuhei, Tozuka, Takehiro, Saito, Ryota, Koyama, Junji, Sakamoto, Hiroaki, Sonoda, Tomoaki, Tsuchiya-Kawano, Yuko, Oba, Tomohiro, Kudo, Keita, Gyotoku, Hiroshi, Nakatomi, Katsumi, Ariyasu, Ryo
Format:	Artikel
Sprache:	eng
Schlagworte:	Cancer Research Enteritis Immune checkpoint inhibitors Immunology Immunosuppressive agents Lung cancer Medicine Medicine & Public Health Oncology Pneumonitis Response rates Steroids
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!